Oppenheimer Reports On ACC Day 2

Oppenheimer has issued a report on the stent data presented at the American College of Cardiology yesterday.

According to the report, "Drug eluting stent data dominated the day yesterday at the American College of Cardiology (ACC) meeting in New Orleans. BSX's Promus Element data delivered with statistically significant non-inferiority to Xience/Promus setting up a mid-2012 (or earlier) launch in the US and Japan that will help drive gross margin expansion as expected. Key BSX risks that remain include continued pricing pressure in stents and CRM as well as competitive CRM product launches from STJ and MDT in '11."